CompoAtlas

LIBRA

Food supplement declared in France, declaration No 2016-5-502

LIBRA is a food supplement declared in France. Status: retrait du marché annoncé pour le 31 December 2026. 1 point in its composition requires a check (prohibited substance, dose or novel food). 2 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
BIOCYTE
Status
Retrait du marché annoncé pour le 31 December 2026
Form
Gélule
Daily dose
3 gélules
Directions for use
Prendre 3 gélules par jour avec un grand verre d'eau
Intended populations
Femme
Not recommended for (according to the manufacturer)
Enfants (moins de 12 ans), Femmes enceintes
Objectives stated by the manufacturer (these are not authorised claims)
Tonus sexuel

Declaration 154584, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Tribulus terrestris L.FruitExtrait sec aqueux150 mg
Lepidium meyenii Walp.RacineExtrait sec aqueux112.5 mg
Vitis vinifera L.FruitAutre extrait sec75 mg
Ilex paraguariensis A. St.-Hil.FeuilleExtrait sec aqueux42.3 mg
Malus pumila Mill.FruitExtrait sec hydroalcoolique33 mg
Crocus sativus L.StigmatesPoudre (de plantes séchées ou broyées)12 mg

Other active ingredients

NamePer day
Théaninenot declared
Citrullinenot declared
N-acétyl L-tyrosinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
NicotinamideNicotinamide (vitamine B3)900 mg54 mg

Additives

E171, E122, E1450, E470b, E551

Other ingredients

maltodextrine, gélatine

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Label warnings

Déconseillé aux enfants et femmes enceintes. L'azorubine peut avoir des effets indésirables sur l'activité et l'attention chez les enfants. Contient de la caféine (16,2 mg maximum par jour), déconseillé aux enfants et femmes enceintes.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Enter to analyse, Shift+Enter for a new line